Table 2.
Demographic and baseline characteristics of participants
| Placebo (n=50) | SNG001 (n=48) | |||
|---|---|---|---|---|
| Age at inclusion, years | 56·5 (11·9) | 57·8 (14·6) | ||
| Sex | ||||
| Male | 31 (62%) | 27 (56%) | ||
| Female | 19 (38%) | 21 (44%) | ||
| Ethnicity | ||||
| White | 39 (78%) | 39 (81%) | ||
| Non-White | 11 (22%) | 9 (19%) | ||
| Comorbidities | ||||
| All | 27 | 26 | ||
| Hypertension | 11/27 (41%) | 18/26 (69%) | ||
| Chronic lung condition | 12/27 (44%) | 11/26 (42%) | ||
| Cardiovascular disease | 8/27 (30%) | 5/26 (19%) | ||
| Diabetes | 9/27 (33%) | 3/26 (12%) | ||
| Cancer | 1/27 (4%) | 0 | ||
| Severity of disease at baseline* | ||||
| No limitation of activities | 1 (2%) | 0 | ||
| Limitation of activities | 1 (2%) | 0 | ||
| Hospitalised (no oxygen therapy) | 19 (38%) | 11 (23%) | ||
| Oxygen by mask or nasal prongs | 28 (56%) | 36 (75%) | ||
| Non-invasive ventilation or high-flow oxygen | 1 (2%) | 1 (2%) | ||
| Duration of symptoms, days† | 9·5 (7·0–12·0) | 10·0 (8·0–11·0) | ||
| Current smoking status | ||||
| Currently uses tobacco | 1 (2%) | 1 (2%) | ||
| Former smoker | 16 (32%) | 11 (23%) | ||
| Never smoked | 33 (66%) | 36 (75%) | ||
Data are n (%) or mean (SD), unless otherwise indicated, and are presented for the intention-to-treat population.
*
Severity of disease at baseline followed the WHO Ordinal Scale for Clinical Improvement.
†
Duration of symptoms is presented as median (IQR).